Abstract
Exposure to a highly nickel-polluted environment has the potential to cause a variety of adverse health effects, such as the respiratory tract cancers. Since numerous studies have demonstrated that nickel generally has weak mutagenic activity, research focus had turned to cell signalling activation leading to gene modulation and epigenetic changes as a plausible mechanism of carcinogenesis. Previous studies have revealed that nickel compounds can induce the expression of vascular endothelial growth factor (VEGF), which is a key mediator of angiogenesis both in physiological and pathologic conditions. In the present study, we investigated the potential roles of PI-3K, ERKs, p38 kinase and calcium signalling in VEGF induction by nickel in Cl 41 cells. Exposure of Cl 41 cells to nickel compounds led to VEGF induction in both time- and dose-dependent manners. Pre-treatment of Cl 41 cells with PI-3K inhibitor, wortmannin or Ly294002, resulted in a striking inhibition of VEGF induction by nickel compounds, implicating the role of PI-3K in the induction. However, mTOR, one of downstream molecules of PI-3K, may not contribute to the induction because pre-treatment of Cl 41 cells with its inhibitor, rapamycin, did not show obvious decrease in nickel-induced VEGF expression. Furthermore, pre-treatment of Cl 41 cells with MEK1/2-ERKs pathway inhibitor, PD98059, significantly inhibited VEGF induction by both NiCl2 and Ni3S2, whereas p38 kinase inhibitor, SB202190, did not impair the induction. Pre-treatment of Cl 41 cells with intracellular calcium chelator, but not calcium channel blocker, inhibited VEGF induction by nickel. Collectively these data demonstrate that PI-3K, ERKs and cytosolic calcium, but not p38 kinase, play essential roles in VEGF induction by nickel compounds.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- DMSO:
-
dimethyl sulfoxide
- ERK:
-
extracellular signal–regulated kinases
- FBS:
-
fetal bovine serum
- HIF-1:
-
hypoxia-inducible Factor-1
- JNK:
-
c-Jun N-terminal kinase
- MAPK:
-
mitogen-activated protein kinase
- MEM:
-
Eagle's minimal essential medium
- mTOR:
-
mammalian target of rapamycin
- PI-3K:
-
phosphotidylinositol 3-kinas
- TGF-β1:
-
transforming growth factor beta 1
- TPA:
-
12-O-tetradecanoylphorbol-13-acetate
- VEGF:
-
vascular endothelial growth factor
References
Kasprzak KS, Sunderman FW Jr, Salnikow K: Nickel carcinogenesis. Mutat Res 533: 67–97, 2003
Andrew A, Barchowsky A: Nickel-induced plasminogen activator inhibitor-1 expression inhibits the fibrinolytic activity of human airway epithelial cells. Toxicol Appl Pharmacol 168: 50–57, 2000
Barchowsky A, Soucy NV, O'Hara KA, Hwa J, Noreault TL, Andrew AS: A novel pathway for nickel-induced interleukin-8 expression. J Biol Chem 277: 24225–24231, 2002
Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, Isner JM: Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189–31195, 1995
Zhou D, Salnikow K, Costa M: Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res 58: 2182–2189, 1998
Salnikow K, Cosentino S, Klein C, Costa M: Loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol Cell Biol 14: 851–858, 1994
Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985, 1983
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309, 1989
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669–676, 2003
Blagosklonny MV: Antiangiogenic therapy and tumor progression. Cancer Cell 5: 13–17, 2004
Dor Y, Porat R, Keshet E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 280: C1367–1374, 2001
Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25, 1997
Salnikow K, Donald SP, Bruick RK, Zhitkovich A, Phang JM, Kasprzak KS: Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem 279: 40337–40344, 2004
Li J, Davidson G, Huang Y, Jiang BH, Shi X, Costa M, Huang C: Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Res 64: 94–101, 2004
Costa M, Klein CB: Nickel carcinogenesis, mutation, epigenetics, or selection. Environ Health Perspect 107: A438–439, 1999
Salnikow K, Blagosklonny MV, Ryan H, Johnson R, Costa M: Carcinogenic nickel induces genes involved with hypoxic stress. Cancer Res 60: 38–41, 2000
Semenza G: Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol 64, 993–998, 2002
Costa M, Yan Y, Zhao D, Salnikow K: Molecular mechanisms of nickel carcinogenesis: Gene silencing by nickel delivery to the nucleus and gene activation/inactivation by nickel-induced cell signaling. J Environ Monit 5: 222–223, 2003
Samet JM, Graves LM, Quay J, Dailey LA, Devlin RB, Ghio AJ, Wu W, Bromberg PA, Reed W: Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am J Physiol 275: L551–558, 1998
Govindarajan B, Klafter R, Miller MS, Mansur C, Mizesko M, Bai X, LaMontagne K Jr, Arbiser JL: Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med 8: 1–8, 2002
Huang C, Ma WY, Dong Z: Requirement for phosphatidylinositol 3-kinase in epidermal growth factor-induced AP-1 transactivation and transformation in JB6 P+ cells. Mol Cell Biol 16: 6427–6435, 1996
Huang C, Schmid PC, Ma WY, Schmid HH, and Dong Z: Phosphatidy- linositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J Biol Chem 272: 4187–4194, 1997.
Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303–324, 1993
Hazzalin CA, Mahadevan LC: MAPK-regulated transcription: A continuously variable gene switch? Nat Rev Mol Cell Biol 3: 30–40, 2002
Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 8: 402–411, 1996
Mukhopadhyay D, Akbarali HI: Depletion of [Ca2+]i inhibits hypoxia-induced vascular permeability factor (vascular endothelial growth factor) gene expression. Biochem Biophys Res Commun 229: 733–738, 1996
Krasilnikov MA: Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 65: 59–67, 2000
El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ: Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63: 5173–5177, 2003
Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193–202, 2002
Gannon G, Mandriota SJ, Cui L, Baetens D, Pepper MS, Christofori G: Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res 62: 603–608, 2002
Wang G, Dong Z, Xu G, Yang Z, Shou C, Wang N, Liu T: The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 124: 615–620, 1998
Milanini J, Vinals F, Pouysségur J, Pagès G: p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 273: 18165–18172, 1998
Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS: Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60: 490–498, 2000
Mottet D, Michel G, Renard P, Ninane N, Raes M, Michiels C: Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 194: 30–44, 2003
Alfranca A, Gutierrez MD, Vara A, Aragones J, Vidal F, Landazuri MO: c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 22: 12–22, 2002
Bulavin DV, Fornace AJ Jr: p38 MAP Kinase's Emerging Role as a Tumor Suppressor. Adv Cancer Res 92: 95–118, 2004
Venkatachalam K, van Rossum DB, Patterson RL, Ma HT, Gill DL: The cellular and molecular basis of store-operated calcium entry. Nat Cell Biol 4: E263–272, 2002
Arnould T, Michiels C, Alexandre I, Remacle J: Effect of hypoxia upon intracellular calcium concentration of human endothelial cells. J Cell Physiol 152: 215–221, 1992
Metzen E, Fandrey J, Jelkmann W: Evidence against a major role for Ca2+ in hypoxia-induced gene expression in human hepatoma cells (Hep3B). J Physiol 517: 651–657, 1999
Author information
Authors and Affiliations
Corresponding author
Additional information
The first two authors have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Ouyang, W., Li, J., Shi, X. et al. Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression. Mol Cell Biochem 279, 35–43 (2005). https://doi.org/10.1007/s11010-005-8214-3
Issue Date:
DOI: https://doi.org/10.1007/s11010-005-8214-3